Skyrizi (risankizumab) is a medication used to treat adults with certain types of plaque psoriasis, psoriatic arthritis, and Crohn’s disease, which are all autoimmune disorders. Skyrizi works by targeting a specific protein in the immune system called interleukin-23 (IL-23), which is responsible for causing inflammation in these conditions. Skyrizi helps reduce inflammation, which improves the symptoms of these conditions, by attaching to and blocking IL-23.
Skyrizi is a monoclonal antibody that belongs to a class of medications called interleukin-23 antagonists. Skyrizi is given as a subcutaneous injection for plaque psoriasis and psoriatic arthritis, and for Crohn’s disease, it is given as an intravenous infusion for the induction period, then as a subcutaneous injection for maintenance dosing.
Skyrizi is FDA approved to treat:
- Plaque Psoriasis moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
- Psoriatic Arthritis active psoriatic arthritis in adults.
- Crohn’s Disease moderately to severely active Crohn’s disease in adults.
